Presolicitation Notice - Illumina NextSeq 2000 Sequencing System
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT942726QJBS4
NAICS
334516 - Analytical Laboratory Instrument Manufacturing
Classification Code
6515
Additional Details
The Defense Health Agency (DHA), operating through its Contracting Activity at Fort Detrick, Maryland, has issued a presolicitation notice indicating its intent to procure an Illumina NextSeq 2000 Sequencing System on a sole source basis from Illumina, Inc. This acquisition is driven by the urgent need to replace the laboratory’s existing Illumina NextSeq 550 system, which is approaching end-of-life, in support of the Armed Forces Medical Examiner System (AFMES) and the Defense POW/MIA Accounting Agency (DPAA). The primary mission is to facilitate the identification of missing U.S. service members from World War II, Korea, Vietnam, and the Cold War, in accordance with the National Defense Authorization Act (NDAA) 2010 mandate for 200 annual identifications.
The scope of this procurement encompasses the direct replacement of the current sequencing platform to ensure continuity of validated Next-Generation Sequencing (NGS) workflows, which are critical for forensic DNA analysis. The Illumina NextSeq 2000 is specified as the only system capable of meeting the technical and operational requirements without incurring prohibitive costs or mission delays. Transitioning to a different manufacturer would necessitate a complete redevelopment and revalidation of all sequencing assays, estimated to cost over $2.8 million and take 24–36 months, resulting in unacceptable delays and potential mission stoppage.
Key requirements for the Illumina NextSeq 2000 Sequencing System include:
- Full compatibility with existing, forensically validated in-house NGS assays for whole mitochondrial DNA (mtDNA) genome and nuclear Single Nucleotide Polymorphism (SNP) analysis.
- Integration of cluster generation and sequencing into a single workflow with onboard data analysis.
- Utilization of XLEAP Sequencing by Synthesis (SBS) chemistry, offering 2.5x faster processing and higher fidelity than previous versions, essential for current laboratory assays.
- Superior data quality, with ≥90% of bases exceeding Q30 for common read lengths.
- Support for flexible read lengths (2x50 bp, 2x100 bp, 2x150 bp, 2x300 bp) using Illumina reagents.
- Output capacity of up to 120 Gb per run and up to 400 million single reads per run, accommodating increased sample throughput.
- Run times ranging from approximately 8 to 42 hours, depending on assay and configuration.
- Integrated reagent cartridge design, eliminating the need for instrument wash cycles between runs.
- Modern touchscreen interface and RFID tracking for all consumables.
- Direct, on-site architectural upgrade path to another NextSeq 2000 System for future scalability.
- Internal instrument control computer meeting or exceeding: 2U Microserver, Linux OS, 288 GB RAM, 3.8 TB SSD.
- Physical dimensions not exceeding 55 cm (W) x 65 cm (D) x 60 cm (H) and a gross weight of no more than 141 kg (311 lbs).
The procurement will be conducted under simplified acquisition procedures, with no set-aside restrictions. The applicable North American Industry Classification System (NAICS) code is 334516 (Analytical Laboratory Instrument Manufacturing), with a small business size standard of 1,000 employees. The place of performance is Dover Air Force Base, Delaware.
This presolicitation notice is not a request for competitive proposals, and no solicitation document currently exists. However, interested parties may submit capability statements, including technical data and cost information, to demonstrate their ability to meet the government’s requirements. All submissions will be considered for the purpose of determining whether to conduct a competitive procurement, though the government reserves sole discretion in making this determination.
Capability statements must be submitted via email to Jeffrey Sprecher at [email protected] by 12:00 P.M. EST on August 18, 2026. No phone inquiries will be accepted.
For contractors specializing in analytical laboratory instrument manufacturing, particularly those with experience in forensic DNA sequencing platforms, this opportunity is highly specialized and tailored to the unique operational needs of the Department of Defense’s identification missions. The technical requirements and mission-critical nature of the acquisition underscore the necessity for proven compatibility, reliability, and scalability in sequencing technology.
Further details and updates can be found on the official SAM.gov opportunity page: https://sam.gov/opp/5b8780b69a154d7b8bfa4701edbfb269/view.